Table 2 Clinicopathological characteristics of patients according to the model-based risk group.
Variables | Total | Low-risk (n = 91) | High-risk (n = 73) | p value |
|---|---|---|---|---|
Age, year | ||||
Mean (SD) | 62.84 (10.67) | 63.55 (10.65) | 61.94 (10.69) | 0.340 |
Sex | ||||
Male | 91 (55.5%) | 45 (49.5%) | 46 (63.0%) | 0.114 |
Female | 73 (44.5%) | 46 (50.5%) | 27 (37.0%) | |
RFS, day | ||||
Mean (SD) | 1034.86 (555.42) | 1178.57 (521.26) | 855.71 (547.83) | < 0.001 |
OS, day | ||||
Mean (SD) | 1292.13 (483.20) | 1341.74 (458.93) | 1230.29 (508.24) | 0.143 |
Tumor invasion size | ||||
Mean (SD) | 3.19 (1.76) | 2.76 (1.43) | 3.75 (1.97) | < 0.001 |
Predominant histologic type | ||||
Lepidic | 5 (3.0%) | 5 (5.5%) | 0 (0.0%) | < 0.001 |
Acinar | 61 (37.2%) | 38 (41.8%) | 23 (31.5%) | |
Papillary | 43 (26.2%) | 30 (33.0%) | 13 (17.8%) | |
Solid | 33 (20.1%) | 8 (8.8%) | 25 (34.2%) | |
Micropapillary | 4 (2.4%) | 2 (2.2%) | 2 (2.7%) | |
Cribriform | 4 (2.4%) | 1 (1.1%) | 3 (4.1%) | |
Mucinous | 14 (8.5%) | 7 (7.7%) | 7 (9.6%) | |
IASLC grade | ||||
1 | 7 (4.3%) | 6 (6.6%) | 1 (1.4%) | < 0.001 |
2 | 51 (31.1%) | 45 (49.5%) | 6 (8.2%) | |
3 | 106 (64.6%) | 40 (44.0%) | 66 (90.4%) | |
PD component, % | ||||
Mean (SD) | 49.09 (38.60) | 30.23 (34.66) | 72.60 (29.34) | < 0.001 |
CGP component, % | ||||
Mean (SD) | 19.49 (25.16) | 14.12 (20.93) | 26.19 (28.34) | < 0.001 |
Necrosis | ||||
Absent | 100 (61.0%) | 71 (78.0%) | 29 (39.7%) | < 0.001 |
Present | 64 (39.0%) | 20 (22.0%) | 44 (60.3%) | |
STAS | ||||
Absent | 50 (30.5%) | 37 (40.7%) | 13 (17.8%) | 0.003 |
Present | 114 (69.5%) | 54 (59.3%) | 60 (82.2%) | |
Pleural invasion | ||||
Absent | 105 (64.0%) | 70 (76.9%) | 35 (47.9%) | 0.001 |
PL1 | 27 (16.5%) | 10 (11.0%) | 17 (23.3%) | |
PL2 | 19 (11.6%) | 8 (8.8%) | 11 (15.1%) | |
PL3 | 13 (7.9%) | 3 (3.3%) | 10 (13.7%) | |
Lymphovascular invasion | ||||
Absent | 84 (51.2%) | 62 (68.1%) | 22 (30.1%) | < 0.001 |
Present | 80 (48.8%) | 29 (31.9%) | 51 (69.9%) | |
pT stage | ||||
pT1 | 70 (42.7%) | 52 (57.1%) | 18 (24.7%) | < 0.001 |
pT2 | 58 (35.4%) | 26 (28.6%) | 32 (43.8%) | |
pT3 | 26 (15.9%) | 10 (11.0%) | 16 (21.9%) | |
pT4 | 10 (6.1%) | 3 (3.3%) | 7 (9.6%) | |
pN stage | ||||
pN0 | 117 (71.8%) | 75 (83.3%) | 42 (57.5%) | < 0.001 |
pN1 | 17 (10.4%) | 3 (3.3%) | 14 (19.2%) | |
pN2 | 29 (17.8%) | 12 (13.3%) | 17 (23.3%) | |
Stage group | ||||
I | 93 (56.7%) | 64 (70.3%) | 29 (39.7%) | < 0.001 |
II | 33 (20.1%) | 13 (14.3%) | 20 (27.4%) | |
III | 36 (22.0%) | 14 (15.4%) | 22 (30.1%) | |
IV | 2 (1.2%) | 0 (0.0%) | 2 (2.7%) | |
